Literature DB >> 18523148

Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.

David C Taussig1, Farideh Miraki-Moud, Fernando Anjos-Afonso, Daniel J Pearce, Kirsty Allen, Christopher Ridler, Debra Lillington, Heather Oakervee, Jamie Cavenagh, Samir G Agrawal, T Andrew Lister, John G Gribben, Dominique Bonnet.   

Abstract

Immunodeficient mice are increasingly used to assay human hematopoietic repopulating cells as well as leukemia-initiating cells. One method commonly used to isolate these rare cells is to sort cells stained with fluorochrome-conjugated antibodies into fractions, then transplant the different fractions into immunodeficient mice to test their repopulating ability. The antibodies are generally treated as being neutral in terms of their effects on the experiment. Human repopulating cells are thought to express CD34 and lack CD38. Here we present evidence that anti-CD38 antibodies have a profound inhibitory effect on engraftment of cord blood and leukemia cells. We show that this effect is Fc-mediated and can be overcome by treating mice with immunosuppressive antibodies. When this inhibitory effect is prevented, we demonstrate that the CD34(+)CD38(+) fraction of certain acute myeloid leukemia samples contains all, or at least most, leukemia-initiating cell capacity. This study highlights the potential pitfall of antibody-mediated clearance of repopulating cells and is important for any groups working with this model. More importantly, the work suggests that there is greater variation in the phenotypes of leukemia-initiating cells than previously suggested.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523148     DOI: 10.1182/blood-2007-10-118331

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  157 in total

1.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

Review 2.  Cancer stem cells: a stride towards cancer cure?

Authors:  Amitava Sengupta; Jose A Cancelas
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

Review 3.  Prostate cancer stem cell biology.

Authors:  C Yu; Z Yao; Y Jiang; E T Keller
Journal:  Minerva Urol Nefrol       Date:  2012-03       Impact factor: 3.720

Review 4.  Concise review: Cancer stem cells and minimal residual disease.

Authors:  Gabriel Ghiaur; Jonathan Gerber; Richard J Jones
Journal:  Stem Cells       Date:  2012-01       Impact factor: 6.277

Review 5.  [Tumor stem cell research - basis and challenge for diagnosis and therapy].

Authors:  Heidrun Karlic; Harald Herrmann; Axel Schulenburg; Thomas W Grunt; Sylvia Laffer; Irina Mirkina; Rainer Hubmann; Medhat Shehata; Brigitte Marian; Edgar Selzer; Michael Pfeilstöcker; Elisabeth Pittermann; Ulrich Jäger; Hubert Pehamberger; Christoph Zielinski; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2010-07-22       Impact factor: 1.704

Review 6.  Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Authors:  J U Marquardt; V M Factor; S S Thorgeirsson
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

Review 7.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 8.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

Review 9.  Cancer stem cells: relevance to SCT.

Authors:  T Lin; R J Jones; W Matsui
Journal:  Bone Marrow Transplant       Date:  2009-02-23       Impact factor: 5.483

Review 10.  TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2013-09-18       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.